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Abstract
The early life gut microbiota plays a crucial role in regulating and maintaining the 
intestinal barrier, with disturbances in these communities linked to dysregulated re-
newal and replenishment of intestinal epithelial cells. Here we sought to determine 
pathological cell shedding outcomes throughout the postnatal developmental period, 
and which host and microbial factors mediate these responses. Surprisingly, neona-
tal mice (Day 14 and 21) were highly refractory to induction of cell shedding after 
intraperitoneal administration of liposaccharide (LPS), with Day 29 mice showing 
strong pathological responses, more similar to those observed in adult mice. These 
differential responses were not linked to defects in the cellular mechanisms and 
pathways known to regulate cell shedding responses. When we profiled microbiota 
and metabolites, we observed significant alterations. Neonatal mice had high rela-
tive abundances of Streptococcus, Escherichia, and Enterococcus and increased pri-
mary bile acids. In contrast, older mice were dominated by Candidatus Arthromitus, 
Alistipes, and Lachnoclostridium, and had increased concentrations of SCFAs and 
methyamines. Antibiotic treatment of neonates restored LPS-induced small intes-
tinal cell shedding, whereas adult fecal microbiota transplant alone had no effect. 
Our findings further support the importance of the early life window for microbiota-
epithelial interactions in the presence of inflammatory stimuli and highlights areas 
for further investigation.
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1 |  INTRODUCTION
Early life represents a critical developmental window, which 
lays the foundations for short- and long-term health.1,2 
Immediately after birth, the human gastrointestinal (GI) tract 
is colonized by a succession of microbes, up until 2-3 years 
of age when the “adult” microbiota fully establishes. This 
early life ecosystem is relatively simple in composition, 
with Bifidobacterium the dominant bacterial genus, which 
is linked to their ability to digest breast milk-derived di-
etary components (ie, human milk oligosaccharides), with 
Bacteroides, Veillonella, Faecalibacterium, Streptococcus, 
and Escherichia also important microbiota members.1,3 
Notably, several factors influence the development of the 
early life microbiota, including mode of delivery, host genet-
ics, diet, and drugs (eg, antibiotics), with disturbances linked 
to an increasing number of immune-linked diseases including 
ulcerative colitis (UC), arthritis, and atopic allergy.2,4,5
During early life the gut microbiota plays a key role in 
development and maturation of numerous host responses.6 A 
central interface mediating these interactions is the intesti-
nal lumen, which represents a unique ecological environment 
that is the major site for microbial-host crosstalk. Indeed, 
recent studies indicate that the microbiota, and certain mi-
crobiota members, modulate transcriptional and functional 
intestinal epithelial cell (IEC) responses through patholog-
ical and immune-mediated mechanisms.7,8 A central output 
of these interactions is the reinforcement of the gut barrier, 
which is achieved through constant replenishment of cells.9 
IECs are “born” in the crypts of Lieberkuhn from where 
they migrate to the tips of the intestinal villi and are lost into 
the intestinal lumen through a homeostatic process known 
as cell shedding.10,11 Cell shedding represents an important 
host physiological response which ensures continuity of the 
intestinal epithelial layer despite continuous replacement of 
IECs every 3-5  days.12 Crucially, intestinal inflammation 
is correlated with elevated or “pathological” cell shedding, 
which is also correlated with altered microbiota profiles.13-15 
Previous studies have indicated that antibiotic usage, and 
antibiotic-induced microbiota perturbations, particularly in 
infancy, are linked to increased risk of developing inflamma-
tory disorders in later life.16 More recently, research, includ-
ing our own, has shown important links between members 
of the intestinal microbiota and the cell shedding response 
in vivo, demonstrating that early life members of the gut mi-
crobial community (ie, Bifidobacterium) can drive protection 
against pathological cell shedding in adult mice.17,18
Although previous studies have demonstrated that there are 
numerous microbiota-mediated effects on IECs during neona-
tal development,19 there are no studies focussed on the role 
of early life gut microbiota during pathological cell shedding. 
Here, we sought to determine how postnatal development 
stage impacts pathological cell shedding using an established 
in vivo model. We used histological, immune, and microbial/
metabolite profiling to assess intestinal barrier function in 
early life and understand the mechanisms involved in regu-
lating this response. Intriguingly, we observed a protective ef-
fect in neonatal mice during LPS-induced epithelial shedding 
when compared to adult counterparts, which was diminished 
after fecal microbiota transplant (FMT) and antibiotic-in-
duced microbiota disturbances, highlighting the crucial role 
the microbiota plays during this important early life period.
2 |  MATERIALS AND METHODS
2.1 | Animals
All mouse experiments were performed under the UK 
Regulation of Animals (Scientific Procedures) Act of 1986. 
The project licences PDADA1B0C and PPL80/2545 under 
which these studies were carried out was approved by the UK 
Home Office and the UEA Animal Welfare Ethical Review 
Body. Time-mated female C57BL/6 Jax mice and female 
adult C57BL/6 Jax mice (aged 6-10  weeks) were obtained 
from Charles River UK. All animals were maintained in the 
UEA Disease Modeling Unit under a standard 12 hours light/
dark cycle and fed standard rodent chow and water ad libitum 
under specific pathogen-free (SPF) conditions.
2.2 | Induction of cell shedding and tissue 
collections
At 14, 21, and 29 days postpartum, pups (n = 6 per group) or 
adult control mice (n = 6) received an intraperitoneal (IP) in-
jection of 1.25mg/kg liposaccharide (LPS) from Escherichia 
coli 0111:B4 (Sigma), 0.5mg/kg murine Tumor Necrosis 
Factor Alpha (TNF-ɑ: 315-01A, Peprotech) or sterile saline 
(control). Mice were sacrificed 90  minutes post-challenge 
with LPS/ TNF-ɑ. At autopsy, proximal small intestine was 
collected in 10% neutral buffered formalin (Sigma) and fixed 
for 24 hours. Samples of proximal small intestine and spleen 
were also collected into RNA later for transcriptome analysis 
or frozen on dry ice for subsequent analysis (Figure 1A).
2.3 | Fecal microbiota transplant
To determine the effects of the microbiota in the protec-
tion against LPS shedding we altered the gut microbiota 
with a combination of antibiotics and FMT from adult mice 
as per Table  1 and Figure  5A. Ciprofloxacin and ampicil-
lin provide a broad range spectrum combination that targets 
Gram-positive and Gram-negative bacteria, thereby effec-
tively knocking down the wider murine resident microbiota. 
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Dosing was determined based on previous published studies, 
and  because both can also transfer to the infant (ie, pup) via 
breast milk (Drugs and Lactation database).20,21 At 10 days 
postpartum (D10) group 2 and 3 had 100 µg/mL of ciproflox-
acin and 500 µg/mL of ampicillin added to the cage drink-
ing water for 5 days to deplete the microbiota. After 5 days, 
both groups received normal drinking water for the rest of the 
study. For the FMT, two to three fecal pellets were collected 
from the control group Dam. Contents were gently homog-
enized using sterile glass beads and sterile PBS and passed 
through a 0.7 µm filter, with 50 µL of solution given to each 
pup by oral gavage. FMT’s were prepared daily, and pups 
were orally gavaged once a day from D16 to D20.
2.4 | Histology
Formalin fixed tissue was dehydrated through a graded ethanol 
and xylene series and embedded in paraffin wax. About 5 μm 
sections were used for immunohistochemistry. Following de-
paraffinization and rehydration, tissue sections were treated with 
1% hydrogen peroxide in methanol to block endogenous per-
oxidases. Subsequently, slides were treated using heat-induced 
antigen retrieval in 0.01M citrate acid buffer (pH 6) followed 
by antibody staining. CC3 staining was performed using rabbit 
polyclonal anti-active Caspase-3 antibody (AF835, R&D sys-
tems) and peroxidase-labeled anti-rabbit EnVision secondary 
antibody (Dako) or DAB or mouse polyclonal Caspase-3 anti-
body (NB100-56708H Novus Biologicals LTD) and visualized 
with DAB peroxidase (HRP) substrate kit (SK-4100, Vector 
Laboratories LTD). Rabbit polyclonal anti-active Caspase-3 
antibody BrdU staining was performed using Sheep anti-BrdU-
biotin (ab2284, Abcam) and neutravidin-HRP (31030, Pierce). 
TNF-R1 staining was performed using rabbit Anti-TNF-R1 an-
tibody (sc-7895, Santa Cruz) and peroxidase-labeled anti-rabbit 
EnVision secondary antibody (Dako). Following secondary an-
tibody binding, signal was detected using 3,3′-diaminobenzi-
dine (Vector) followed by counterstaining with hematoxylin.
2.5 | Caspase-3 quantification
IECs were counted on a cell positional basis from villus tip 
(Cell position (CP) 1) down toward the crypts under 400× 
magnification. 20 well-orientated hemi-villi were counted 
per mouse and analyzed using the Score, WinCrypts22 and 
PRISM (version 8) analysis software. IECs were defined 
as “normal” in cases where staining for active Caspase-3 
was absent. Immuno-abeled cells with either unaltered or 
shedding morphology were treated as Caspase-3 positive. 
IEC's stained with mouse polyclonal anti-active Caspase-3 
antibody (NB100-56708H) were visualized with DAB and 
staining intensity was measured using FIJI (ImageJ 1.52h, 
National Institutes of Health, USA). Imaging was with an 
Olympus BX60 microscope and C10plus digital camera.
2.6 | ELISAs
Murine TNF-ɑ or Murine IL-10 Ready set go enzyme-linked 
immunosorbent assay (ELISA) kits were used (eBioscience). 
Protocol was performed as per manufacturer's instructions. 
In brief, Costar 9018 ELISA plates were coated with 100 µL/
well of capture antibody diluted in Coating Buffer overnight 
at 4°C followed by blocking with ELISASPOT diluent. Small 
intestinal samples were homogenized in Cell Lytic MT buffer 
(Sigma) using Lysing matrix E beads (MP Biomedicals) and 
homogenates cleared by centrifugation at 10  000  rpm for 
15 minutes. After quantification using BCA kit (Pierce), equiv-
alent amounts of test samples or standard material were applied 
to wells in duplicate and incubated overnight at 4°C. Detection 
Antibody, Streptavidin-HRP and substrate were then applied, 
and plates were read at 450 nm with 570 nm correction.
2.7 | Western blots
Spleens were homogenized in Cell Lytic buffer using 
Lysing matrix E beads (MP Biomedicals) and homogen-
ates cleared by centrifugation at 10 000  rpm for 15 min-
utes. Homogenates were quantified by BCA analysis 
and 10 mg of total protein separated by SDS-PAGE with 
10% acrylamide resolving gel. Proteins were then trans-
ferred to Hybond-P PVDF membrane (GE Healthcare). 
Immunostaining was performed with 1/100 anti-MYD88 
antibody (ab2064, Abcam) and 1/2000 Goat anti-Rabbit 
IgG HRP conjugate (Millipore) or 1/5000 Rabbit Anti-
Beta-Actin antibody (ab8227, Abcam) and 1/5000 Goat 
anti-rabbit HRP. Signal was detected using ImmobilonTM 
Western chemiluminescent HRP substrate (Millipore) and 
the FluorChem E imaging system (Protein Simple).
2.8 | Cytokine antibody array
Small intestinal samples were homogenized in Cell Lytic 
MT buffer (Sigma) using Lysing Matrix E beads (MP 
T A B L E  1  Treatment groups for FMT and antibiotic studies
Group Group name
Antibiotic (Abx) 
treatment
Fecal microbiota 
transfer (FMT)
1 Control No No
2 Abx control Yes No
3 Abx + FMT Yes Yes
4 FMT No Yes
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Biomedicals) at a concentration of 50mg/ml. Homogenates 
were then cleared by centrifugation at 10  000  rpm for 
15  minutes before quantification of protein using BCA 
kit (Pierce). About 250 mg of total protein was then used 
to probe Murine antibody inflammation arrays (Abcam; 
ab133999) as per manufacturer's instructions. In brief, 
membranes were for 30  minutes before application of 
homogenized whole small intestinal lysates in blocking 
buffer overnight at 4°C. Following washing, biotin con-
jugated anti cytokine antibodies were applied for 2 hours 
before further washing and application of HRP conjugated 
streptavidin. Chemiluminescent detection was then per-
formed using supplied detection reagents and visualization 
performed using FluorChem E imaging system (Protein 
Simple). See Table S1 for plate layout.
2.9 | Isolation of IECs
IECs were isolated using a modification of the Weisser 
method.23 Briefly, whole small intestine was opened lon-
gitudinally, chopped into c.a. 5  mm2 pieces and washed 
in 0.154  M sodium chloride (NaCl) containing 1  mM 
Dithiothreitol (DTT). Intestine was then incubated in a salt 
solution containing 1.5  mM Potassium Chloride (KCl), 
96 mM NaCl, 27 mM Tri-sodium citrate (Na3C6H5O7), 8mM 
sodium di-hydrogen phosphate (NaH2PO4), and 5.6mM di-
sodium hydrogen phosphate (Na2HPO4), pH 7.3 for 15 min-
utes at 37°C with gentle shaking (140 rpm). Epithelial cells 
were then stripped from mucosa by further incubation in 
PBS containing 1.5mM Ethylene diamine tetraacetic acid 
(EDTA) and 0.5 mM DTT for 15 minutes at 37°C, 140 rpm. 
Epithelial cells were then recovered and stabilized by pel-
leting at 1000 rpm for 5 minutes followed by lysis in buffer 
RLT RNA lysis solution (Qiagen).
2.10 | Isolation of DNA and 16S rRNA 
sequencing and analysis
Mouse fecal samples were collected into Lysis Matrix 
D tubes from the same mice at Day 14, 21, and 29. Adult 
fecal samples were collected from both parents at the same 
time as Day 14 samples. DNA extraction was carried out 
using a FastDNA Spin Kit for Soil (SKU 116560200-CF, 
MP Bioscience) following the manufacturers protocol with 
the exception of extending the bead-beating step to 3 min-
utes. DNA was quantified using a Qubit® 2.0 fluorometer 
(Invitrogen). 16S rRNA region (V1-V2) primers were used 
for library construction (Table S2), with the following PCR 
conditions; cycle of 94°C 3 minutes and 25 cycles of 94°C for 
45 seconds, 55°C for 15 seconds, and 72°C for 30 seconds. 
Sequencing of the 16S rRNA gene libraries was performed 
using Illumina MiSeq platform with 300 bp paired-end reads. 
Raw reads were filtered through quality control using trim 
galore (version 0.4.3), minimum quality threshold of phred 
33, and minimum read length of 60  bp. Reads that passed 
threshold were aligned against SILVA database (version: 
SILVA_132_SSURef_tax_silva) using BLASTN (ncbi-
blast-2.2.25+; Max e-value 10e−3) separately for both pairs. 
After performing BLASTN alignment, all output files were 
imported and annotated using the paired-end protocol of 
MEGAN on default Lowest Common Ancestor (LCA) pa-
rameters.24 For analysis of microbiota composition, the sam-
ples were normalized by subsampling each sample to 3224 
reads (the number of reads of the lowest sample) to equalize 
library sizes using the Phyloseq package version 1.24.2 in 
RStudio version 1.1.463.
2.11 | Isolation of RNA, cDNA 
synthesis, and real-time PCR
RNeasy plus mini-spin columns were used to isolate total 
RNA (Qiagen). In brief, samples were homogenized using 
a rotor stator hand-held homogenizer in buffer RLT (tissue 
samples) or reconstituted in buffer RLT by pipetting (isolated 
IECs). Lysates were processed through QIAshreddor col-
umns (Qiagen) and subsequently RNeasy mini-spin columns. 
Purified RNA was eluted into RNAase free water.
For TNF-R1 real-time PCR analysis of isolated IECs, 
cDNA was synthesized using Quantitect reverse tran-
scription kit (Qiagen) and real-time PCR performed 
using Quantitect SYBR green mastermix (Qiagen) and 
Quantitect murine TNF-R1 primer assay (Qiagen) or hy-
poxanthine–guanine phosphoribosyltransferase (HPRT) 
5′-GACCAGTCAACAGGGGACAT-3′ (sense) and 
5′-AGGTTTCTACCAGTTCCAGC-3′ (antisense) primers. 
Cycling was performed on a Roche LightCycler 480 using 
the following conditions: 95°C, 5 minutes then 40 cycles of 
95°C, 10  seconds; 60°C, 35  seconds. Relative quantifica-
tion of levels of transcript expression was calculated using 
the Pfaffl method by comparing cycle threshold (CT) value 
of each target gene to the CT value of housekeeper.25 Data 
are presented as a “fold change” in expression (normalized 
against control untreated mice per cells).
For PCR array analysis, reverse transcription was per-
formed using the Transcriptor first strand cDNA synthesis 
kit (Roche) and cDNA analyzed on custom real-time ready 
384 well custom PCR arrays (Roche). Arrays contained the 
following murine targets: IL-1B, Ml2, Arrdc2, Bid, Card6, 
Casp4, Cycs, Ikbe, Rel, Tlr2, Traf5, Tnfrs8, Tnfrsf1b, 
Tnfrs19, Bd2l1, Rn18s, Il6, Alpi, Pdzd7, Casp12, Card11, 
Casp7, Fadd, Nkb1, Rela, Traf6, Traf2, Tnfrs9, Tnfrs11b, 
Tnfrs15, Bd2l10, Rpl13a, Il10, Pdx1, Apaf1, Card10, Casp3, 
Casp9, Fas, Nkb2, Relb, Traf3, Traf7, Tnfsf11, Tnfsf25, 
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Tnfsf21, Bfar, Ptgds, Ifng, Ceacam10, Bad, Casp1, Caps6, 
Cd40lg, Fasl, Nkbia, Serpinb2, Tnf, Tnfsf18, Tnfsf8, Tnfsf4, 
Tnfsf14, Ephb3, Ptgs2, Col18a1, Pzp, Bax, Card9, Casp2, 
Cd40, Faslk, Nkbib, Serpinb9, Traf1, Tnfsf10, Tnfrsf10b, 
Tnfrsf1a, Tnfsf18, Hprt1, Ddk1, Gasdma, Fgl1, Bd2, Casp14, 
Casp8, Cflar, Ikbkb, Nod2, Actb, B2m, Gapdh.
Cycling was performed using Lightcycler 480 probe mas-
ter mix and a Roche LightCycler 480 using the following 
conditions: 95°C, 10 minutes then 40 cycles of 95°C, 10 sec-
onds; 60°C, 30 seconds, 72°C, 1 seconds. Final analysis of 
CT values was using the DDCT method as described above.
2.12 | 1H NMR metabolomics
Stomach contents were collected from mice at autopsy and 
immediately frozen on dry ice before transfer to −80°C 
prior to analysis. Small intestinal contents were flushed 
from the duodenum using sterile water and frozen simi-
larly prior to analysis. 1H nuclear magnetic resonance 
(NMR) was used to identify the presence and concentration 
of several metabolites. Supernatant samples were thawed 
at room temperature and prepared for 1H NMR spectros-
copy by mixing ~50 mg (FW) of stomach content samples 
with 600 µL of NMR buffer (0.26 g NaH2PO4 and 1.41 g 
K2HPO4) made up in 100% D2O (100  mL), containing 
0.05% NaN3 (50 mg), and 1 mM sodium 3-(Trimethylsilyl)-
propionate-d4, (TSP) (17 mg) as a chemical shift reference. 
The sample was mixed, and 500  µL was transferred into 
a 5-mm NMR tube for spectral acquisition. The 1H NMR 
spectra were recorded at 600  MHz on aBruker Avance 
spectrometer (Bruker BioSpin GmbH, Rheinstetten, 
Germany) running Topspin 2.0 software and fitted with a 
5 mm TCI cryoprobe. Sample temperature was controlled 
at 300 K. Each spectrum consisted of 512 scans of 65,536 
complex data points with a spectral width of 12.3  ppm 
(acquisition time 2.66  seconds). The noesypr1d pre-satu-
ration sequence was used to suppress the residual water 
signal with low-power selective irradiation at the water 
frequency during the recycle delay (D1 = 3 s) and mixing 
time (D8 = 0.01 s). A 90° pulse length of 12.9 μs was set 
for all samples. The “noesypr1d” pre-saturation sequence 
was used to suppress the residual water signal with a low-
power selective irradiation at the water frequency during 
the recycle delay. Spectra were transformed with a 0.3-Hz 
line broadening, manually phased, baseline corrected, and 
referenced by setting the TSP methyl signal to 0 ppm. The 
metabolites were quantified using the software Chenomx 
NMR suite 7.6. Metabolites were identified using infor-
mation found in the literature (references) or on the web 
(Human Metabolome Database, http://www.hmdb.ca/) and 
by the use of the 2D-NMR methods, COSY, HSQC, and 
HMBC.
2.13 | Statistics
Results were plotted and analyzed using PRISM version 8 
software (GraphPad). Data (mean + SD) were analyzed using 
ordinary one-way ANOVA with Tukeys posttest with a 95% 
confidence interval. Cleaved caspase-3 (CC3) was measured 
using FIJI (Fiji Contributions) and plotted as mean fluores-
cence intensity (MFI) from three sections per mouse (n = 7). 
Microbiota and metabolome data analysis was carried out in 
R version 3.5.0 using RStudio (version 1.1.463). The “veg-
dist” function in the “vegan” (version 2.5.4) R package was 
used to calculate Bray-Curtis dissimilarity matrices for the 
microbiota abundance and metabolomics data. NMDS plots 
of Bray-Curtis matrices were generated for microbiota data 
using the vegan package. Permutational multivariate analysis 
of variance (PERMANOVA) was performed on Bray-Curtis 
matrices using the “pairwiseAdonis” package. Diversity 
analysis of microbial abundance data was performed using 
the “vegan” package. Statistical analysis of number of genera 
and Shannon diversity between groups was performed using 
Kruskal-Wallis one-way analysis of variance with Pairwise 
Wilcoxon Rank Sum Tests using Benjamini-Hochberg step-
wise adjustment.
3 |  RESULTS
3.1 | Neonatal mice are refractory to LPS-
induced pathological cell shedding
We previously demonstrated that IP administration of 
LPS-induced potent cell shedding in adult mice with peak 
response 90  minutes post injection as determined by CC3 
staining.17,26 To assess cell shedding response of neonatal 
mice, 14- and 21-day-old mice were administered with either 
low (1.25 mg kg-1) or high (10 mg kg-1) dose LPS (or PBS 
vehicle control) and sacrificed 90 minutes post-administra-
tion (Figure 1A). Surprisingly, IECs in 14- and 21-day-old 
mice were CC3 negative following low-and high-dose LPS 
and villi exhibited normal histology at the macroscopic level 
(Figure 1B,C). We next treated 29-day-old neonatal mice with 
IP LPS and observed the re-emergence of cell shedding re-
sponse (Figure 1B,D). As expected, adult mice (8-10 weeks) 
showed enhanced cell shedding responses as determined by 
CC3 positive cells and associated pathology within the small 
intestine (Figure 1B,E).
We reasoned that absence of CC3 staining in neonates 
may be the result of delayed IEC apoptosis. To test this hy-
pothesis, 14-day-old neonatal mice were administered low-or 
high-dose LPS and tissue collected up to 180 minutes post-
LPS administration. In contrast to adult mice which show ex-
tensive CC3 staining at 90 minutes coupled with associated 
villus atrophy at later time points, neonatal mice showed no 
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evidence of CC3 staining up to 180 minutes post-LPS, nor 
evidence of pathological changes that normally accompany 
the cell shedding response (data not shown). Taken together, 
mice are largely refractory to LPS-induced cell shedding 
during the neonatal period, with intermediate responses ob-
served in Day 29 old mice, with adult mice very susceptible 
to pathological cell shedding. These distinctions cannot be 
explained by altered kinetics of cell death responses during 
the early life developmental period.
3.2 | Cell signalling pathways that drive 
pathological cell shedding are expressed in 
neonatal mice
Previous work suggests that systemically delivered LPS sig-
nals via mononuclear cells which express TLR4. This signal-
ing cascade is mediated by the TLR-adaptor protein MYD88, 
which drives production of TNF-ɑ, which in turn binds 
TNFR1 expressed on the surface of IECs and triggers ap-
optosis and cell shedding.26 We reasoned that this signaling 
cascade may be diminished in neonatal mice, thus preventing 
initiation of the cell shedding response. IECs were isolated 
from the mucosa of neonatal (Day 14), and adult mice and 
expression of TNF-R1 determined by real-time PCR. Levels 
of TNFR1 transcript was significantly increased in control 
neonatal mice compared to adult mice, but neonates dosed 
with LPS had significantly reduced TNFR1 (Figure 2A). We 
next reasoned that production of TNF-ɑ in neonatal mice may 
be impaired. However, ELISA analysis of whole small in-
testinal homogenates from Day 14 neonatal mice exposed to 
low-and high-dose LPS confirmed production of TNF-ɑ at 
levels comparable to adult mice (Figure 2B).
Previous studies have shown reduced expression of MYD88 
protein in human neonatal peripheral blood leukocytes, and 
we hypothesized that altered MYD88 expression in neonatal 
mice may drive reduced cell shedding.27 However, there were 
no significant differences in the levels of MYD88 protein in 
F I G U R E  1  Neonatal mice are refractory to LPS-induced cell shedding. A, Experimental workflow for LPS/TNF-α administration and tissue 
collection. B, Immunohistochemical analysis of cleaved-caspase 3 (CC3) on hematoxylin stained intestinal tissue demonstrated absence of cell 
shedding at Day 14 with only occasional cell shedding events observed at Day 21. Mice at Day 29 demonstrated emergence of cell shedding in 
response to LPS administration. Inset images show representative control tissue. C-E, Wincrypts software was used to quantitate cell shedding 
events in 50 representative half villi, shown as percentage CC3 positive versus cell position from the villus tip. Significant difference in rate of 
observed cell shedding events (P < .0001) was found between adult and neonatal tissue. White scale bar 100 μm
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homogenized spleen samples taken from 14-day-old and adult 
mice (Figure 2C). To confirm our findings indicating there are 
no neonatal defects in cell shedding signaling pathways we also 
challenged mice IP with TNF-ɑ. Whilst adult mice showed the 
expected potent cell shedding response, neonatal mice were 
largely refractory to cell shedding, with only isolated cell shed-
ding events observed (Figure 2D). Taken together, this suggests 
that core components of the cell shedding signaling pathways 
are intact in neonatal mice and that blunting of the cell shedding 
response cannot be explained by altered expression profiles of 
these components at the transcriptional and translational level.
3.3 | Inflammatory responses are altered in 
neonatal versus adult mice during pathological 
cell shedding
PCR and antibody arrays were used to explore if differing 
cell shedding outcomes in neonatal mice may be driven by 
alterations in immunologic/inflammatory responses and/or in 
expression of bacterial recognition markers. We observed re-
duced expression of pro-inflammatory markers such as IFN-γ 
but increased anti-inflammatory cytokines such as IL-10 in neo-
natal mice versus adults following LPS stimulation (Figure 3A). 
We also observed altered expression of transcripts associated 
with bacterial recognition including nucleotide-binding oli-
gomerization domain-like receptors (NODs) and members of 
TNF receptor-associated proteins including TRAF1, TNFrsf10, 
and TNFrsf21, alongside changes to components of the apop-
totic cascade including reduced expression of CARD9, 10, 11, 
and Casp3 (Figure 3B). At a translational level we observed 
elevation of IL-10, IL-7, IL-12, and TNF-ɑ in neonatal versus 
adult mice during pathological cell shedding, with the increased 
IL-10 levels in neonatal mice confirmed by ELISA (Figures S1 
and S3C). These data indicate that neonatal mice may have a 
more anti-inflammatory and anti-apoptotic milieu when com-
pared to their adult counterparts, which may be in part driving 
altered cell shedding responses.
F I G U R E  2  Neonates do not have impaired TNF signaling pathways. Expression and protein quantification were used to investigate the 
molecular basis of differential cell shedding responses of neonatal and adult mice. A, TNF-R1 expression was quantified by real-time RT-PCR in 
isolated intestinal epithelial cells and showed control neonates had higher expression (with the opposite observed in LPS-treated mice). B, ELISA 
analysis of TNF-α expression in whole small intestinal homogenates showed no significant difference between induction of TNF- α in Day 14 versus 
adult mice. C, Western blot analysis of MYD88 protein in murine spleen tissue confirmed similar levels of expression in neonatal (Day 14) and adult 
mice. D, Challenge with IP TNF-α (0.5 mg/kg) confirmed that neonatal mice were largely refractory to TNF-α-induced cell shedding versus adult 
counterparts. Statistical analysis performed by one-way ANOVA with Tukeys posttest (n = 5 ± 2 ***P < .001, *P < .05, ns = not significant)
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3.4 | Microbiota profiles and microbial-
derived metabolites are significantly altered in 
neonatal mice when compared to adults
Previous studies have indicated that the neonatal microbiota 
significantly influences immune and epithelial responses.28 
Moreover, humans and mice show distinct alterations in mi-
crobiota composition during the early life developmental 
window, and our previous work highlighted the importance 
of (early life) gut microbes in regulating the cell shedding re-
sponse. Thus, we sought to determine how microbial profiles 
diversify at key postnatal time points which also correspond 
to the observed differences in cell shedding responses.
The bacterial composition of fecal samples was deter-
mined by 16S rRNA amplicon sequencing and analysis. 
Genus level clustering of samples using non-metric multidi-
mensional scaling (NMDS) indicated separation of the mi-
crobiota profiles between Day 14 from Day 21, Day 29 and 
adult mice (PERMANOVA comparisons P  =  .006), while 
Day 21 mice showed a more divergent microbiota that was 
separate from Day 29 mice (PERMANOVA comparison 
P  =  .006), which clustered closely with adult (maternal) 
mouse samples (Figure  4A). The clustering of the micro-
biota composition in Day 14 mice was driven by the genus 
Streptococcus while Day 21 mice showed a divergent micro-
biota composition driven in part by Lactobacillus abundance. 
Day 29 mice clustered with the adult samples with the com-
position driven by genera including Roseburia, Bilophila, 
and Alistipes (Figure 4A).
We observed that number of genera detected, and the 
Shannon diversity index increased during the neonatal pe-
riod; with the lowest number of genera in Day 14 mice com-
pared to Day 21, Day 29, and adult mice (Figures S2A,B). 
We also examined the 30 most abundant genera by relative 
abundance from Day 14, 21, 29, and adult mice using Bray-
Curtis dissimilarity (Figure 4B), showing that Day 14 mice 
samples clustered with a distinct microbiota composition 
comprised of Streptococcus, Staphyloccous, Escherichia, 
and Enterococcus that were absent from older samples while 
Lachnoclostridium, Roseburia, Candidatus Arthromitus (or 
F I G U R E  3  Neonatal mice have altered immune and apoptosis pathways. PCR arrays were used to assess global transcriptional changes in 
neonatal versus adult intestinal epithelial cells using a custom panel of epithelial/ cell shedding related targets. Panels (A) and (B) show the global 
transcriptional changes observed. Specific signaling molecules where substantive changes in expression were observed and which are discussed 
in the associated text are marked. We also assessed IL-10 expression in whole small intestinal homogenates by ELISA. Significant elevation of 
IL-10 in response to LPS challenge was observed in Day 14 (P < .0001) and Day 21 neonatal mice (P < .001), but not in Day 29 or adult mice (C). 
Statistical analysis performed by one-way ANOVA with Tukeys posttest (n = 5 ± 2 ****P < .0001, ***P < .001, ns = not significant)
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F I G U R E  4  Neonatal mice have altered microbiota genus composition and duodenum metabolite composition. Sequencing analysis of 
fecal samples taken from mice aged 14, 21, and 29 days and 10-week-old adult mice. A, Bray-Curtis-based non-metric multidimensional scaling 
(NMDS) plot of fecal microbiota samples shows distinct grouping for Day 14 and 21 mice but with a distinct shift toward D29 and into adulthood. 
B, Heat map shows relative abundance of the 30 most abundant genera clustered using a Bray-Curtis dissimilarity and indicates increased diversity 
during the weaning period. C, Relative abundance of genera in each sample grouped by day of age. D, Relative abundance of NMR analysis of 
metabolites in duodenum contents clustered by Bray-Curtis dissimilarity shows distinct grouping for Day 14 mice with a greater proportion of 
cholate and tauro-cholate and an absence of glycine and leucine
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Segmented filamentous bacteria), and Alistipes became dom-
inant by 29 days and in adult mice. This composition was also 
illustrated with the relative abundance within in mouse sam-
ple (Figure 4C). Interestingly, the 21-day-old group appeared 
to have a more varied microbiota profile between animals, 
possibly linked to the rapidly changing nutritional environ-
ment during this period (ie, moving from maternal milk to 
solid food) (Figure 4C).
We next performed 1H NMR analysis of duodenal and 
stomach contents harvested from neonatal and adult mice 
to profile changes in metabolites (Figures  4D and S2C,D). 
Day 14 mice duodenum samples clustered separately with a 
higher proportions of the bile acids cholate and taurocholate 
(Figures 4D and S2J,K), at which time the presence of SN-
glycerol-phosphocholine in the stomach contents indicated 
the milk-based diet at 14 days (Figure S2E,F). Day 14 mice 
also showed an absence of leucine and glycine from duode-
num contents potentially linked to their milk diet (Figure S2I-
M). The appearance of the microbial metabolites propionate 
and trimethylamine in stomach contents at Day 21 and 28 
indicated the start of coprophagy and the potential expo-
sure and transfer of new microbes between neonatal mice. 
These changes suggested dramatic shifts in microbiota and 
metabolic profiles during the neonatal period related to 
changes in diet, which correlates with distinct responses to 
LPS-induced cell shedding.
3.5 | Microbiota composition and antibiotic-
induced microbiota disturbances modulate 
pathological cell shedding responses
Next, we determined if the protective responses observed 
in neonatal mice were associated with differences in the 
microbiota and metabolite profiles as seen in Figure 4. We 
performed an FMT experiment whereby we dosed neonatal 
mice (Day 16) with adult (dam) fecal samples (8-10 weeks) 
for 5 days via oral gavage, with further groups also treated 
with antibiotics (via drinking water for 5  days) to deplete 
the resident neonatal microbiota (alone), and in combination 
with FMT. On D21 all group received LPS by IP injection 
(Figure  5A). Histopathological analysis of small intestine 
showed that adult FMT alone was insufficient to significantly 
disrupt intestinal pathology (Figure  5B). However, disrup-
tion of the neonatal microbiota with antibiotics significantly 
increased damage to the epithelium, which was not reversed 
F I G U R E  5  Neonatal mice have LPS shedding responses after FMT and antibiotic treatments. A, FMT and antibiotic treatments were 
performed to disrupt the microbiota and assess the impact of LPS on cell shedding in D21 old mice (previously shown to be refractory to LPS-
induced pathology). B, Semi quantitative analysis of ileum by histopathology confirmed D21 mice were protected from damage caused by LPS. 
Neonatal mice that received FMT at D16-D20 showed no increase (P = .7587) in damage. Both Abx and Abx + FMT groups had significantly 
increased damage (P < .0001 and 0.0007 respectively). C and D, Apoptotic cell death was analyzed using anti-cleaved caspase 3 (CC3). D21 
mice had little to no apoptotic cell death which was significantly increased (P < .0001) across all FMT and Abx dosed groups. Statistical analysis 
performed using one-way ANOVA with Dunnett's posttest n = 5. Scale bar 100 µm
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by FMT from adult mice (Figure 5B). Neonatal mice treated 
with antibiotics (Day 10-14) with and without adult FMT 
had significantly increased apoptotic cell death (measured by 
CC3 intensity) (Figure 5B,C). Although we did not observe 
a significant increase in intestinal pathology/damage scores 
from FMT alone, we did observe that FMT induced a sig-
nificant increase in apoptotic cell death (Figure 5D). These 
data indicate that the neonatal microbiota plays a key role in 
modulating cell shedding.
4 |  DISCUSSION
Using a mouse model of pathological intestinal cell shed-
ding, we report that neonatal mice are largely refractory to 
LPS-induced epithelial cell death. Our data suggest a close 
association between the intestinal microbiota and developing 
immune system during the postnatal period that induces pro-
tection in this key early life window. Moreover, disturbances 
of these pioneer microbial communities with antibiotics an-
tagonises protective responses, highlighting the important 
role of the neonatal microbiota in regulating host physiology 
in health and disease.
The intestinal epithelium is the first line of defence be-
tween the luminal gut contents and the host. IEC integrity 
is maintained by a delicate balance of proliferation and cell 
shedding in the intestinal crypts and tips of the villi, respec-
tively.9 As such, regulation and maintenance of barrier integ-
rity at the intestinal epithelial interface is vital to prevent entry 
of luminal microbes into the systemic circulation that may in-
duce detrimental inflammatory responses. Indeed, there is a 
strong correlation between altered cell shedding and initiation 
of inflammatory conditions demonstrating the need to better 
understand the mechanistic links between cell shedding and 
disease progression.13 Many intestinal inflammatory disor-
ders present clinically in adolescents and adults, and we have 
previously shown that it is possible to dampen down patho-
logical cell shedding in adult mice by supplementing with an 
early life microbiota member (ie, Bifidobacterium breve).17 
However, it has been suggested that early life events, which 
directly impact the infant/neonatal microbiota (such as diet 
and antibiotics), may shape the initiation of inflammatory 
cascades and IEC barrier integrity.29 As such, addressing the 
role of the microbiota in regulating cell shedding in neonates 
is important and necessary to help develop our understanding 
of how these diseases evolve in children and adolescents.
To our surprise day-14-old mice were completely refrac-
tory to LPS-induced cell shedding, with limited cell shedding 
events in mice aged 21 days, and emergence of substantive 
cell shedding responses from Day 29 postpartum. These data 
indicate that there is a “tipping” point for induction of in-
flammatory cell shedding responses, which may correlate 
with the period when the microbiota becomes “adult-like”. 
Initially, we reasoned this reduced cell shedding may be 
linked to the operation of cellular signaling pathways that 
have previously been shown to modulate cell shedding re-
sponse. However, neonates were competent in these aspects, 
including TNF-ɑ production, the functional cytokine that 
initiates apoptotic signaling cascades.26 Nevertheless, we did 
note differential expression of other immune components in 
neonates (compared to adults), particularly IL-10 and IFN-
Ɣ. IL-10 is a prototypical anti-inflammatory cytokine which 
inhibits the synthesis of pro-inflammatory cytokines such as 
TNF-ɑ and IFN-Ɣ thus limiting pathological cell shedding 
responses.30 IL-10 induction has previously been described to 
be driven by certain microbiota members such as Bacteroides, 
Bifidobacterium and Helicobacter, suggesting that specific 
members may play a key role for inducing anti-inflammatory 
and anti-apoptotic responses, thereby driving protective bar-
rier integrity during the neonatal period.31-34
Our previous studies demonstrated an important role for 
infant-associated Bifidobacterium breve, which reduced 
pathological cell shedding processes in adult mice via the 
bifidobacterial exopolysaccharide capsule and host MyD88 
signaling interactions.17,35 Although Bifidobacterium 
is found at high levels in infants, species and strains of 
this genus are not consistently detected in neonatal mice. 
Indeed, our microbiota profiling indicated very low levels 
of this taxa in our mice (0.7%), highlighting other early 
life bacterial members may be involved in the protective 
cell shedding responses at days 14 and 21. We observed 
lower microbial diversity in Day 14 mice, when compared 
to their older counterparts, with correspondingly low con-
centrations of duodenum and stomach metabolites; simi-
lar to the relatively “simple’ infant microbial ecosystems.1 
Notably, we observed high relative abundance of typical 
early life facultative anaerobic species such as Escherichia 
and Streptococcus.3,36 Previous studies in germ-free and 
conventional mice have indicated E coli plays a crucial 
role in immune programming, including signaling via 
E coli-associated flagella (via TLR5). The intestinal epi-
thelium represents a central interface for these two-way in-
teractions with recent work showing that IEC expression of 
TLR5 is a critical step in promoting luminal colonisation of 
flagellated bacteria (eg, E coli); a window which closes at 
Day 21 postpartum when TLR5 is downregulated.37 Other 
dominant neonatal microbiota members include Gram-
positive Enterococcus which has previously been shown 
(newborn-associated Enterococcus faecalis) to possess the 
ability to regulate certain cell signaling pathways, which 
results in transcriptional activation of IL-10 (increased in 
Day 14 old mice).38 Crucially, as well as Escherichia, we 
also observed increased abundances of the Gram-negative 
Parabacteroides in neonatal mice. LPS also plays an im-
portant role in homeostatic immune modulation, alongside 
induction of pathological inflammatory responses as seen 
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in our LPS-induced cell shedding model. Previous studies 
have indicated that immune cells are programmed to se-
crete inflammatory cytokines in response to LPS stimula-
tion, and then become refractory to further stimulation (ie, 
“exhausted”).39 Moreover, the order Bacteroidales (which 
includes Parabacteroides) produce a specific type of LPS 
(derived from an underacylated structural feature) that has 
been shown to silence TLR4 signaling, even when exposed 
to other gut microbiota member LPS types.40 This suggests 
that the high relative abundance of these LPS-expressing 
bacteria may serve to downregulate pathological cell shed-
ding responses and provide protection during the neonatal 
window. However, further studies would be required to test 
these hypotheses. Notably, the majority of these neonatal 
microbiota members are not typical bile salt hydrolase en-
coding bacteria, which may indicate why we observed a 
higher proportion of primary bile acids cholate and tau-
rocholate within the small intestine.41 The effects of bile 
acids are complex, with previous studies indicating that bile 
acids can inhibit apoptosis and/or augment proliferative 
responses in IECs.42 However, signaling through the bile 
salt receptor farnesoid X receptor has been demonstrated to 
promote anti-inflammatory effects in models of intestinal 
inflammation, and thus may link with our observations and 
the absence of pathological cell shedding during the neona-
tal developmental window.43 Another elevated metabolite 
at Day 14 was SN-glycerol-phosphocholine; accumulation 
of phosphatidylcholine in the intestinal mucus layer is cru-
cial for the protection of the IEC barrier from microbial ex-
posure, and UC patients have been shown to have reduced 
phosphatidylcholine.44 Although further studies would be 
required to probe the role of these specific metabolites in 
our experimental cell shedding model, it does suggest that 
specific neonatal microbiota members and the metabolite 
milieu may contribute to the protective responses observed.
The Day 21 postnatal period appears to show the most 
dynamic and variable microbial profile in mice, which may 
correlate with the “mixed” nutritional exposure, that is, milk 
and mouse chow/coprophagy. In these Day 21 mice, cell sig-
naling responses induced at earlier time points (by early life 
microbiota members) may help maintain epithelial barrier 
integrity. This, coupled with absence or very low levels of 
other microbiota members present in older mice, may serve 
to override protective neonatal programming to allow typical 
pathological cell shedding. Weaning itself (and the start of 
coprophagia in mice) is associated with the emergence of a 
more adult-like microbiota. Notably, by Day 29 postpartum, 
the intestinal microbiota showed greater similarity to the ma-
ternal community than at Day 14 and Day 21, with elevated 
relative abundance of Candidatus Arthromitus, Alistipes, and 
Lachnoclostridium. Segmented Filamentous Bacteria (ie, 
Candidatus Arthromitus) are often considered mouse-asso-
ciated commensals, which can penetrate the intestinal mucus 
layer and intimately associate with IECs initiating immune 
responses, particularly inflammatory IL-17-associated re-
sponses.22,45 Moreover, facultative Alistipes spp. can overgrow 
in genetically susceptible mouse models which is correlated 
with induction of inflammatory colitis, thus linking presence 
of this taxa to the enhanced cell shedding responses observed 
in Day 29 and adult mice.46 Metabolomic profiling of the in-
testinal and stomach contents demonstrated emergence of a 
greater number of bacterial metabolites which coincided with 
the weaning period. These included microbial metabolites 
such as the SCFAs butyrate, propionate, and acetate. SCFAs 
can act either as substrates for host cell metabolism and/or as 
signaling molecules, particularly induction of immune sig-
naling cascades via G-protein-coupled receptors (GPCRs).47 
Previous studies have implicated SCFA-receptors signaling 
in chronic inflammatory diseases, which may occur via a va-
riety of mechanisms. Both propionate and butyrate treatment 
has been linked with increased chemotaxis of immune cells 
including neutrophils, which are an important cell type impli-
cated in acute inflammatory-associated intestinal damage.48 
Furthermore, mice treated with SCFAs (propionate and bu-
tyrate) have enhanced IEC proliferative activity and turn-
over, which may correlate with the increased inflammatory 
responses observed in adult mice and enhanced pathological 
cell shedding.49,50 Further SCFA supplementation studies are 
required to probe these findings.
Due to the significant differences in microbiota and me-
tabolite profiles in the postnatal age groups, we hypothesised 
that disrupting the neonatal microbiota with clinically rele-
vant antibiotics would induce pathological cell shedding, 
thereby linking with studies that have shown that early life 
antibiotic usage correlates with increased risk of developing 
intestinal disorders.51 Indeed, antibiotic exposure of neona-
tal mice prior to Day 21 postpartum led to a significant in-
crease in the cell shedding response. We also proposed that 
emergence of the adult-like microbiota may represent the 
first, permissive step toward enabling cell shedding in this 
model. However, when neonatal mice were colonized with an 
adult microbiota (alone, without prior antibiotic treatment), 
we only observed enhancement of apoptosis (caspase 3), 
but not a concurrent increase in intestinal pathological fur-
ther suggesting that it is the neonatal microbiota maintaining 
the epithelial barrier in response to inflammatory stimulus. 
Further work should seek to explore this early life window in 
greater detail to further interrogate the nature of the protec-
tive response, and the key microbial drivers and metabolites 
involved in this modulation.4
In conclusion, our work has provided important new in-
sights into the role of the early life intestinal microbiota in 
regulating the intestinal epithelium, barrier function and the 
immune system. It suggests a complex interplay between 
these compartments in protecting the neonatal gut from 
pathological cell shedding during the critical period of early 
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life. These data may provide a platform for the development 
of therapies aimed at reducing chronic intestinal diseases in 
paediatric and adult patient populations.
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